Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

November 20, 2017

Oral Presentation of Long Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease

CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical trial of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease will be presented at the New Horizons in Fabry Disease Conference taking place November 24-25 in Prague, Czech Republic.

The oral presentation titled “Enzyme replacement therapies in development – preclinical and clinical data and experience with pegunigalsidase alfa,” will be given by Prof. Raphael Schiffmann, Director, Institute of Metabolic Disease at the Baylor Research Institute, Dallas, Texas, at a session taking place on Friday, November 24 from 4:00 PM to 6:00 PM CET.

Additional details on the conference can be found at http://www.horizons-fabry.com/.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.

Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2952
mnanus@troutgroup.com

Source: Protalix BioTherapeutics, Inc.